NCT06891313 One Stage Ridge Splitting Using 2 Different Techniques in the Posterior Mandible
| NCT ID | NCT06891313 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Ridge Augmentation |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-02-26 |
| Primary Completion | 2025-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-02-26 with a primary completion date of 2025-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The selected patients will be informed of the nature of the research work and informed consent will be obtained. The control group ridge splitting with simultaneous implants using the conventional technique and study group ridge splitting with simultaneous implants using the piezo surgery. * Pre operative procedures Patients of both groups will be subjected to CBCT. * Intra operative procedures (for both groups) followed by CBCT will be taken for every patient after 4 months. * Infiltration local anesthesia will be given to the patient (Articaine 4% 1:100 000 epinephrine). Both the study and control group will receive: * In Recipient site, incision of full thickness mucoperiosteal flap inorder to obtain, three-line pyramidal flap, followed by flap reflection. * The defective site is reevaluated. * Flap advancement using periosteal releasing incision. * In the Study group: Piezo surgery bone inserts are used. * In the Control group: Bone discs diameter are used. * Followed by bone chisels. * The point and pilot implant drills are used followed by the sequential use of bone expanders. Based on the preexisting bone, the defect morphology and bone quality. The implant is submerged below the alveolar crest. * The fixture is inserted submerged below the alveolar bone crest followed by bone smoothening and roundation under external saline irrigation at recommended speed of 38000rpm and gear ratio 1:1 calibrated on fesiodespenser. * Xenogenic bone particle size of 0.5 mm to 1mm is going to be condensed into the dead space. * Recheck adequate flap advancement. * Double line closure using horizontal mattress sutures followed by interrupted sutures on top to allow contact area and wound edge eversion.
Eligibility Criteria
Inclusion Criteria: * Patients with mandibular residual alveolar bone height not less than 8 mm. * Alveolar bone width from 5mm to 3mm. * Both genders. * At least single missing tooth. * Previous failed implants. * Tapered or cylinder cross sectioned alveolar bone defect pattern. Exclusion Criteria: * Heavy smokers more than 20 cigarettes per day. * Patients with bone disease that may affect normal healing, example; hyperparathyroidism. * Patients had radiotherapy and chemotherapy in head and neck. * Patients had neoplasms in sites to be grafted. * Patients with Metabolic diseases uncontrolled diabetic patients, Glycated hemoglobin (Hb A1c) more than 7 mg\\dl. * Pregnant females. * Patients with Para functional habits, apprehensive and non-cooperative. * Bone pathology related to the site to be grafted. * Psychological problems, stress situation (socially or professionally), emotional instability, and unrealistic patients' expectations. * Intraoral soft and hard tissue pathology. * Systemic condition that contraindicates implant placement. * Under the age of 18 years. * Hourglass defects or defects with bone concavities and or undercuts.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06891313 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 48 Years, studying Ridge Augmentation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06891313 currently recruiting?
Yes, NCT06891313 is actively recruiting participants. Contact the research team at mohannadahmed@hotmail.com for enrollment information.
Where is the NCT06891313 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06891313 clinical trial?
NCT06891313 is sponsored by Cairo University. The trial plans to enroll 20 participants.